This suggests that SGLT2 inhibitor treatment improved the clinical manifestations of HF via correction of hyperinsulinemia and insulin resistance located upstream of HF concomitant with T2D. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.